Legend Biotech Corporation has announced promising interim results from a Phase 1 study of LB2102, a DLL3-targeted CAR-T cell therapy, in patients with lung cancers. The study, presented at a recent conference, involved patients with relapsed or refractory small-cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) who had received at least one prior line of therapy. The results indicated that LB2102 was well tolerated, with no dose-limiting toxicities observed up to Dose Level 4. The study also showed encouraging signs of dose-dependent efficacy, with clinical responses correlating with CAR-T cell expansion. These findings support continued dose escalation and further clinical evaluation. Legend Biotech is conducting this study in the U.S. under an exclusive global license agreement with Novartis Pharma AG.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。